Psoriasis

LEO Pharma shared 2 posters with data from the ongoing EFFISAYIL ON program, supporting long-term use of spesolimab for generalized pustular psoriasis.

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

Late-breaking data shared at AAD 2026 supports oral TYK2 envudeucitinib's efficacy and safety in moderate-to-severe plaque psoriasis.

IL-17 inhibitors are highly effective, but many patients still require switching due to treatment failure, loss of response, or intolerance.

Molecular NOS2/CCL27 testing outperforms standard biopsy reads for psoriasis versus eczema, reducing diagnostic uncertainty in CHE and speeding targeted treatment.

Omar Noor, MD, FAAD, discusses strategies to improve psoriasis care for patients facing adherence challenges related to lifestyle or cognitive barriers.

Clinical trial data showed approximately 70% of patients achieved clear or almost clear skin with icotrokinra by week 16.

Chovatiya discusses treat-to-target goals, biologics, BSA remission, and patient burden in psoriasis.

Results show that bimekizumab achieved significantly higher ACR50 response rates at week 16 than risankizumab in adults with active PsA.

Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.

Patients treated with deucravacitinib achieved higher ACR20 response rates at week 16 than those receiving placebo in the POETYK PsA studies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Nicholas Brownstone, MD, and other experts spotlighted cytokine hubs at the 2026 Winter Clinical Miami conference, linking chronic spontaneous urticaria and psoriasis/psoriatic arthritis to smarter targeted treatment choices.

A panel discussion highlights the diagnostic variability, systemic risk, and evolving treatment landscape of GPP.

Real-world data shows Medicare plaque psoriasis patients stay on Sun Pharma’s IL-23 tildrakizumab longer than other systemic therapies.

A poster presented at Winter Clinical Miami 2026 shows tildrakizumab is often preferred for older patients with plaque psoriasis and medically complex comorbidities.

In a 52-week phase 3 study, CT-P43 demonstrated sustained efficacy comparable to reference ustekinumab in adults with moderate to severe plaque psoriasis.

In the phase 3b TOGETHER-PsO trial, ixekizumab plus tirzepatide led to significantly higher rates of complete skin clearance and ≥10% weight loss.

Investigators reported consistent clinical improvement following twice-weekly excimer laser treatments.

Real-world data on psoriasis super responders show that risankizumab drives complete skin clearance for up to 2.5 years.

DISCREET phase 3 research shows oral apremilast eases genital psoriasis symptoms, improving itch, clearance, and sexual quality of life through 32 weeks.

Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.

Icotrokinra emerges as a groundbreaking oral treatment for moderate to severe psoriasis, showing superior efficacy compared with existing therapies at Maui Derm 2026.

Discover insights from the Horizons in Advanced Practice meeting on type 2 inflammation and psoriasis management.

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.